Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × nilotinib × Sarcoma × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 10 OTHER 3 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1

Conditions

Sarcoma 1 Neoplasm Metastasis 1

Interventions

Doxorubicin 3 High-Throughput Nucleotide Sequencing 2 Base Sequence 2 trametinib 1 spartalizumab 1 pembrolizumab 1 palbociclib 1 olaparib 1 nilotinib 1 ipatasertib 1 glasdegib 1 futibatinib 1 durvalumab 1 dactolisib 1 dabrafenib 1 ceritinib 1 capmatinib 1 camrelizumab 1 apatinib 1 anlotinib 1 Zoledronic Acid 1 Valganciclovir 1 Transplantation, Homologous 1 Transplantation, Autologous 1 Rituximab 1 Radiotherapy 1 Psychoanalysis 1 Nivolumab 1 Lapatinib 1 Irinotecan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03784014 2025-12-11

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Active not recruiting

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡